New research indicates that a drug called Inavolisib is effective at treating a type of metastatic breast cancer with a ...

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression, metabolic ...

A large-scale, international, multicentre, phase 3 clinical trial of aspirin for the secondary prevention of colorectal ...

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression ...

Scientists from UF’s College of Veterinary Medicine and the UF Health Cancer Center investigated how mutations in a gene called PIK3CA impact the development and progression of angiosarcoma.

Led by Singapore, a 12-year, international, multi-centre, phase 3 clinical trial of aspirin for the secondary prevention of colorectal cancer in over 1,500 patients has been completed and published in ...

The approval marks the culmination of a long road for Roche in bringing a PIK3CA-targeting drug to market, as its first candidate, called taselisib, was abandoned on safety grounds. It is also the ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

That may be because the non-biomarker group in the study included quite a high proportion of untested patients in whom PIK3CA/AKT1/PTEN status was unknown. Mutations in PIK3CA, AKT1, and ...